Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01655069 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076
A Phase 3 study, sponsored by Astellas Pharma Europe B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 148
- Enrollment target
NCT01655069 is a Phase 3 study that has completed, run by Astellas Pharma Europe B.V.. The registered enrollment target is 148 participants.
The verdict
NCT01655069, a Phase 3 study, has completed, sponsored by Astellas Pharma Europe B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 148 participants
- Enrollment target
Study Summary
This was a 40-week study to investigate how safe and effective solifenacin solution was in treating children or adolescents with symptoms of overactive bladder (OAB), who completed study 905-CL-076 (NCT01565707).
Interventions
- DRUG Solifenacin succinate suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2012-10-04 |
| Est. Completion | 2014-10-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01655069
The ClinicalTrials.gov registry entry for NCT01655069 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Europe B.V., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Solifenacin succinate suspension is the first listed.
NCT01655069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01655069 about?
NCT01655069 is a clinical study titled "A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076". This was a 40-week study to investigate how safe and effective solifenacin solution was in treating children or adolescents with symptoms of overactive bladder (OAB), who completed study 905-CL-076 (NCT01565707).
What is the current status of trial NCT01655069?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 148 participants. The study started on 2012-10-04. Estimated completion is 2014-10-08.
What interventions are being tested in trial NCT01655069?
The interventions under investigation include: Solifenacin succinate suspension (DRUG).
Who is sponsoring clinical trial NCT01655069?
This trial is sponsored by Astellas Pharma Europe B.V., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.